The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20% to 30% of primary human breast cancers and that correlates with poor prognosis. We show that Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Littlepage, Laurie E., Adler, Adam S., Kouros-Mehr, Hosein, Huang, Guiqing, Chou, Jonathan, Krig, Sheryl R., Griffith, Obi L., Korkola, James E., Qu, Kun, Lawson, Devon A., Xue, Qing, Sternlicht, Mark D., Dijkgraaf, Gerrit J. P., Yaswen, Paul, Rugo, Hope S., Sweeney, Colleen A., Collins, Colin C., Gray, Joe W., Chang, Howard Y., Werb, Zena
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3546490/
https://ncbi.nlm.nih.gov/pubmed/22728437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0093
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi